摘要
目的分析恩替卡韦联合扶正化瘀胶囊治疗失代偿期乙型肝炎肝硬化的临床效果。方法选择我院2013年3月至2015年3月收治的失代偿期乙型肝炎肝硬化患者180例为研究对象,按照患者入院顺序分为对照组和联合组,各90例。两组患者均给予临床基本保肝治疗,在此基础上给予对照组患者服用恩替卡韦治疗,联合组患者在对照组用药的基础上联合应用扶正化瘀胶囊治疗。治疗48周后,对两组患者治疗前、后肝纤维化4项指标变化情况及并发症发生率进行比较,并比较两组患者的治疗有效率。结果治疗后,两组患者在的肝纤维化4项指标均优于治疗前,且联合组的各项指标优于对照组(P<0.05);联合组患者并发症发生率明显低于对照组(P<0.05),联合组患者的治疗有效率为98.89%,优于对照组的92.22%(P<0.05)。结论恩替卡韦联合扶正化瘀胶囊治疗失代偿期乙型肝炎肝硬化,近期治疗的临床效果比较满意,值得临床推广应用。
Objective To analyze the clinical effect of entecavir combined with Fuzheng Huayu capsule in the treatment of patients with decompensated liver cirrhosis of hepatitis B. Methods One hundred and eighty patients with decompen- sated liver cirrhosis of hepatitis B in our hospital from March 2013 to March 2015 were selected as research objects, which were divided into control group and combination group according to the order of admission, with 90 cases in each group. Two groups of patients were all given liver-protecting treatment. On this basis, the patients in the control group were given entecavir treatment, while the patients in combination group were given Fuzheng Huayu capsule on the basis of the control group. The 4 indexes of liver fibrosis, complications and effects of the two groups were compared after 48 weeks treatment. Results After treatment, the indexes of liver fibrosis of patients in the two groups were all better than before treatment, and the indexes of the combination group were better than those of the control group （P〈0.05）. The complication rate of the combination group was significantly lower than that of the control group （P〈0.05）. The effective rate of the combination group was 98.89%, which was better than 92.22% of the control group （P〈0.05）. Conclusion Entecavir combined with Fuzheng Huayu capsule has good clinical effect in the treatment of patients with decompensated liver cirrhosis of hepatitis B, which is worthy of clinical application.
出处
《临床医学研究与实践》
2017年第7期54-55,共2页
Clinical Research and Practice
